gdc

Bladder Cancer

Balversa First Targeted Drug Approved for Metastatic Bladder Cancer with FGFR Genetic Alterations
Bladder CancerFDA Approvals, News & Updates
In April 2019, the FDA approved Balversa, an FGFR kinase inhibitor, for the treatment of adults with advanced or metastatic bladder cancer and an FGFR genetic alteration, as determined by an FDA-approved diagnostic test. This is the first FDA-approved targeted drug for patients with this specific genetic mutation.
Drugs for Bladder Cancer
Bladder Cancer
Here are the drugs and financial support services available to patients receiving treatment for Bladder Cancer.
Drugs for Bladder Cancer
Bladder Cancer
Here are the financial support services available to patients receiving treatment for Bladder Cancer.
New Immunotherapy Drugs Are Making Headway in the Treatment of Bladder Cancer
Bladder CancerImmunotherapy
Take a look at the 5 new promising immunotherapies approved by the FDA for bladder cancer after decades of no new treatment options for this type of cancer.
Understanding Bladder Cancer
Bladder Cancer
Bladder cancer is the fourth most common cancer type in men, but many new therapies are now being used. Here’s an excellent overview of the risk factors, symptoms, and treatments.

Results 1 - 5 of 5

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country